SEC Company Response from BioNTech SE (BNTX) (CIK 0001776985) (BNTX) — Feb 3, 2020
BioNTech SE (BNTX) (CIK 0001776985)
Date: Feb. 3, 2020 · CIK: 0001776985 · Accession: 0001193125-20-023031
AI Filing Summary & Sentiment
File numbers found in text: 333-236225
Letter
Underwriters Acceleration Request
J.P. Morgan Securities LLC
BofA Securities, Inc.
SVB Leerink LLC
As Representatives of the
several Underwriters listed
in Schedule 1 hereto
c/o J.P. Morgan Securities LLC
Madison Avenue
New York, New York 10179
c/o BofA Securities, Inc.
One Bryant Park
New York, New York 10036
c/o SVB Leerink LLC
1301 Avenue of the Americas
New York, New York 10019
February 3, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: BioNTech SE
Registration Statement on Form F-1
Filed February 3, 2020
File No. 333-236225
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of BioNTech SE (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Time, on February 5, 2020, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Covington & Burling LLP and Freshfields Bruckhaus Deringer LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, the Underwriters wish to advise you that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
Acting severally on behalf of themselves and the
Show Raw Text
CORRESP 1 filename1.htm Underwriters Acceleration Request J.P. Morgan Securities LLC BofA Securities, Inc. SVB Leerink LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o BofA Securities, Inc. One Bryant Park New York, New York 10036 c/o SVB Leerink LLC 1301 Avenue of the Americas New York, New York 10019 February 3, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: BioNTech SE Registration Statement on Form F-1 Filed February 3, 2020 File No. 333-236225 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of BioNTech SE (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 PM, Eastern Time, on February 5, 2020, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Covington & Burling LLP and Freshfields Bruckhaus Deringer LLP, request by telephone that such Registration Statement be declared effective. Pursuant to Rule 460 under the Act, the Underwriters wish to advise you that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus. We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. Very truly yours, Acting severally on behalf of themselves and the several Underwriters J.P. MORGAN SECURITIES LLC By: /s/ David Ke Name: David Ke Title: Executive Director BOFA SECURITIES, INC. By: /s/ Michele A.H. Allong Name: Michele A.H. Allong Title: Authorized Signatory SVB LEERINK LLC By: /s/ Gabriel Cavazos Name: Gabriel Cavazos Title: Managing Director [Signature Page to Underwriters’ Acceleration Request]